Yizhe Wang, LianBio CEO
December 19, 2022 10:54 AM EST
Deals
R&D

Pfiz­er opts in to net Lian­Bio’s rights to RSV can­di­date, putting down $20M up­front

Tyler Patchen

News Reporter

Pfiz­er and Lian­Bio have had a re­la­tion­ship for over two years now, but the phar­ma’s lat­est move will see it grab a can­di­date from Lian­Bio …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times